Phase 1/2 Study of Atrasentan Combined with Pegylated Liposomal Doxorubicin in Platinum-Resistant Recurrent Ovarian Cancer1

Research output: Contribution to journal › Article › Academic › peer-review

Cite this

@article{bfb0754513f34e3494804bcccb707517,

title = "Phase 1/2 Study of Atrasentan Combined with Pegylated Liposomal Doxorubicin in Platinum-Resistant Recurrent Ovarian Cancer1",

author = "P.O. Witteveen and \{van der Mijn\}, K.J. and M. Los and R.H. Kronemeijer and G. Groenewegen and E.E. Voest",

year = "2010",

language = "English",

volume = "12",

pages = "941--945",

journal = "Neoplasia",

issn = "1522-8002",

publisher = "Elsevier",

number = "11",

}

TY - JOUR

T1 - Phase 1/2 Study of Atrasentan Combined with Pegylated Liposomal Doxorubicin in Platinum-Resistant Recurrent Ovarian Cancer1

AU - Witteveen, P.O.

AU - van der Mijn, K.J.

AU - Los, M.

AU - Kronemeijer, R.H.

AU - Groenewegen, G.

AU - Voest, E.E.

PY - 2010

Y1 - 2010

M3 - Article

SN - 1522-8002

VL - 12

SP - 941

EP - 945

JO - Neoplasia

JF - Neoplasia

IS - 11

ER -